Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.

ABSTRACT:

Rationale

The HLH-94 protocol is a standard induction treatment for hemophagocytic lymphohistiocytosis. However, about 30% of patients may not respond. Ruxolitinib has been clinically proven to be an effective treatment for hemophagocytic lymphohistiocytosis (HLH).

Patient concerns

A previously healthy 14-year-old girl presented to the local hospital with a 4-day history of persistent fever and sore throat.

Diagnosis

Clinical and laboratory tests revealed fever >38.5°C, hepatosplenomegaly, pancytopenia, hypertriglyceridemia, hypofibrinogenemia, hyperferritinemia, and an elevated interleukin-2 receptor level.

Intervention

This patient was treated with ruxolitinib and the HLH-94 protocol.

Outcomes

The patient's clinical and some laboratory indices improved

SUBMITTER: Huang Z 

PROVIDER: S-EPMC7982154 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature